Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Activating mutations of EZH2, an epigenetic regulator, are present in 20% of follicular lymphoma patients. Tazemetostat monotherapy showed clinically meaningful, durable responses. Serious treatment-related adverse events were reported in four (4%) of 99 patients.
